NextGen PeptidesProduct page includes use or preparation wordingIn stock
Tesamorelin · 20 mg × 1 vial
$90.00$4.50 / mg
Checked · 5 days ago
Lab report: Not linked
View product details (opens in a new tab)No commercial relationship
Research listings · Peptides
Tesamorelin research listings: prices and suppliers
Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use.
We have no commercial relationship with suppliers on this page. Offers are sorted by price per mg; commission never changes the order.
Prices observed weekly · last check · How we check prices →
Lowest current at 20 mg × 1 vial$4.50 / mg · $90.00NextGen Peptides · checked 5 days ago
Listings at 20 mg × 1 vial
| Supplier link | |||||||
|---|---|---|---|---|---|---|---|
| NextGen PeptidesProduct page includes use or preparation wording | 20 mg × 1 vial | $90.00 | $4.50 / mg | In stock | 5 d ago | Not linked | View product details (opens in a new tab)No commercial relationship |
| Protide Health | 20 mg × 1 vial | $140.00 | $7.00 / mg | In stock | 5 d ago | Not linked | View product details (opens in a new tab)No commercial relationship |
| Nova Peptide SupplyProduct page includes use or preparation wording | 20 mg × 1 vial | $169.99 | $8.50 / mg | In stock | 5 d ago | Not linked | View product details (opens in a new tab)No commercial relationship |
- Protide HealthIn stock
Tesamorelin · 20 mg × 1 vial
$140.00$7.00 / mg
Checked · 5 days ago
Lab report: Not linked
View product details (opens in a new tab)No commercial relationship - Nova Peptide SupplyProduct page includes use or preparation wordingIn stock
Tesamorelin · 20 mg × 1 vial
$169.99$8.50 / mg
Checked · 5 days ago
Lab report: Not linked
View product details (opens in a new tab)No commercial relationship
Quantity not confirmed · 1
We could not confirm the price or the labelled amount, so these listings are excluded from ranking.
| Supplier link | |||||||
|---|---|---|---|---|---|---|---|
| Ascend ScienceProduct page includes use or preparation wording | 20 mg × 1 vial | Not provided | — | Stock unknown | 5 d ago | Not linked | View product details (opens in a new tab)No commercial relationship |
- Ascend ScienceProduct page includes use or preparation wordingStock unknown
Tesamorelin · 20 mg × 1 vial
Not provided
Checked · 5 days ago
Lab report: Not linked
View product details (opens in a new tab)No commercial relationship
- Prices exclude shipping. A matching name does not verify the contents of a lot.
- Lab reports are vendor-reported, not independently authenticated. “Lab confirmed” means the issuing laboratory confirmed the report is theirs.
- Some suppliers’ product pages include use or preparation wording. We list their prices for comparison only; we do not endorse that wording, and nothing on this site is guidance on preparing or using these materials.
By size
Every package size we track for Tesamorelin. Current means seen in the last 8 days.
| 2 mg × 1 vial | $27.95 | $13.98 / mg | 2 / 2 | 2 |
|---|---|---|---|---|
| 5 mg × 1 vial | $38.00 | $7.60 / mg | 8 / 8 | 7 |
| 10 mg × 1 vial | $50.00 | $5.00 / mg | 9 / 10 | 9 |
| 20 mg × 1 vial | $90.00 | $4.50 / mg | 3 / 4 | 3 |
| 5 mg × 10 vials | $504.00 | $10.08 / mg | 1 / 1 | 1 |
| 10 mg × 10 vials | $656.00 | $6.56 / mg | 2 / 2 | 2 |
Research context
From our own records, with the date each was last checked.
- FDA approval
- Approved: Egrifta (tesamorelin acetate), first approved 2010-11-10; Drugs@FDA lists application 022505 as a BLA (data updated 2026-11-02)Checked
- 503A / 503B compounding
- Not in any 503A category on FDA's 2026-05-14 listChecked
- Advisory committee (PCAC)
- No PCAC meeting on tesamorelin found on FDA's 2022 to 2027 PCAC meeting pages (checked 2026-11-03)Checked
- Rulemaking / enforcement
- No proposed or final rule found in the Federal Register (search on 2026-11-03); FDA matches are 2010 advisory committee notices and a 2012 Egrifta patent-term noticeChecked
- WADA
- S2.2.4 Growth hormone releasing factors: GHRH and its analogues · Prohibited at all times — in and out of competition (2026 list; unchanged in the 2027 list, in force from Jan 1, 2027)Checked
- Identity
- Formula C221H366N72O67S · MW 5136 g/mol · CAS 218949-48-5Sequence (E)-hex-3-enoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2Source record Checked
Identity noteResearch listings are not Egrifta. They are not FDA-approved medicines and are not made or checked by the company that makes Egrifta.
How we check prices · Offers are matched to our catalogue by an editor before they appear; a listing is not an endorsement.